Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)